This is a non-core endpoint: only basic statistics are computed.
Carcinoma in situ of bronchus and lung (controls excluding all cancers)
CD2_INSITU_BRONCHUSLUNG_EXALLC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
individuals
Apply sex-specific rule None
Check conditions
not C3_BRONCHUS_LUNG
Check pre-conditions, main-only, mode, registry filters
Hospital Discharge: ICD-10
D02.2&
Hospital discharge: ICD-9
2312
Cause of death: ICD-10
D02.2&
Cause of death: ICD-9
2312
Cancer registry: Topography ICD-O-3
C34
Cancer registry: Morphology ICD-O-3
ANY
Cancer registry: Behaviour codes
2
3 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints None
-
Remove individuals based on genotype QC
26
CD2_INSITU_BRONCHUSLUNG_EXALLC
Control definitions
Control exclude
C3_CANCER, C3_CANCER_WIDE
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF9
Parent code in ICD-10
D02
Name in latin
Carcinoma in situ mammae
No upset plot: script not run.
No upset table: script not run.
Similar endpoints
↥List of similar endpoints to
Carcinoma in situ of bronchus and lung (controls excluding all cancers)
based on the number of shared cases.
Broader endpoints:
- Carcinoma in situ of bronchus and lung
- Carcinoma in situ of middle ear and respiratory system
- Carcinoma in situ of middle ear and respiratory system (controls excluding all cancers)
- In situ neoplasms
- In situ neoplasms (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 26 | 8 | 18 |
| Unadjusted prevalence (%) | 0.01 | 0.00 | 0.01 |
| Mean age at first event (years) | 69.09 | 71.76 | 67.90 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_INSITU_BRONCHUSLUNG_EXALLC – Carcinoma in situ of bronchus and lung (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Carcinoma in situ of bronchus and lung (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.